Literature DB >> 32683766

Diagnostic performance of transrectal ultrasound for prostate volume estimation in men with benign prostate hyperplasia.

Rotimi A David1, Tajudeen A Badmus1, Abdulkadir A Salako1, Christianah M Asaleye2, Davies Adeloye3, Olubukola Fanimi2, Jacob K Opele4, Adeyinka Laoye1, Ibrahim A Akinbola1, Martin C Igbokwe1, Rereloluwa N Babalola1, Chigozie I Onyeze1.   

Abstract

BACKGROUND AND AIM: Despite transrectal ultrasound (TRUS) being regarded as gold standard for prostate volume estimation, concerns have been raised in the literature concerning its accuracy especially in men with above-average prostate volumes. We aimed to evaluate the performance of TRUS for prostate volume estimation in a cohort of sub-Saharan African men since they are known to have relatively large mean prostate volumes.
METHODS: This was a prospective study of 77 sub-Saharan African men who had open simple prostatectomy for benign prostate hyperplasia (BPH). Pre-operative TRUS determined total prostate volume (TPV) and transition zone volume (TZV). Following surgical enucleation, the adenoma was weighed (EPW) and its volume (EPV) also determined by fluid displacement. TRUS was repeated six weeks post-operatively to calculate the TRUS-estimated specimen volume (TESV).
RESULTS: The mean EPV, EPW, TRUS-estimated TZV, TRUS-estimated TPV and TESV were 79.1 ± 62.9 ml, 79.1 ± 62.9 g, 53.3 ± 28.5 ml, 93.1 ± 48.9 ml and 69.9 ± 44.6 ml, respectively. Pearson's correlation showed a perfect relationship between EPW and EPV with no difference in their mean values (r = 1.000; P < .001). Pearson's correlation between TRUS-estimated TPV vs EPV, TRUS-estimated TZV vs EPV, and between TESV vs EPV were 0.932, 0.865 and 0.930, respectively (P = .0000). TRUS significantly under-estimated the TZV and TESV by 25.8 ml and 9.2 ml, respectively; unrelated to the severity of prostate enlargement.
CONCLUSION: TRUS underestimates prostate volume, independent of prostate size. We propose simple formulae that could be used to improve the prostate volume determination from TRUS, especially if magnetic resonance imaging is not readily available or contraindicated.
© 2020 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2020        PMID: 32683766     DOI: 10.1111/ijcp.13615

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  3 in total

1.  Immediate Transurethral Plasma Kinetic Enucleation of the Prostate Gland for Treatment of Benign Prostatic Hyperplasia-Associated Massive Hemorrhage: A Single-Center Experience.

Authors:  Yu Gan; Liang Deng; Qiangrong He; Chao Li; Leye He; Zhi Long
Journal:  Front Surg       Date:  2022-01-12

2.  Reliability and validity of assessment methods available in primary care for bladder outlet obstruction and benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review.

Authors:  Tom Vredeveld; Esther van Benten; Rikie E P M Beekmans; M Patrick Koops; Johannes C F Ket; Jurgen Mollema; Stephan P J Ramaekers; Jan J M Pool; Michel W Coppieters; Annelies L Pool-Goudzwaard
Journal:  BMJ Open       Date:  2022-04-29       Impact factor: 3.006

3.  Three-dimensional measurement and analysis of benign prostatic hyperplasia.

Authors:  Yankun Feng; Jianhui Wu; He Zhu; Qiming Wang; Tianyi Li; Yong Xu; Ping Zhang; Lidong Zhai
Journal:  Transl Androl Urol       Date:  2021-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.